MedTrace Logo

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2007-10-15

No results posted yet for this study

Summary

In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

DDP225

Sponsors & Collaborators

  • Dynogen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • William Patterson, MD · Hotel Dieu Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00230581 on ClinicalTrials.gov